The Annals of the Rheumatic Diseases (ARD) is a leading international journal devoted to advancing the understanding and treatment of rheumatic and musculoskeletal diseases (RMDs). As a flagship publication of the European Alliance of Associations for Rheumatology (EULAR), ARD publishes cutting-edge research across a broad spectrum of topics including clinical rheumatology, translational research, and epidemiology. It is targeted towards both clinicians and basic scientists.
ARD covers a diverse range of RMDs including rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, spondyloarthritis, and other related conditions. The journal prioritizes articles on disease mechanisms, innovative therapies, outcomes research, and patient-centered care. The journal ensures high-quality research output. ARD is indexed in Medline, Web of Science, and Scopus, ensuring broad discoverability.
The journal emphasizes its commitment to improving patient outcomes and advancing knowledge in rheumatology and musculoskeletal science. It invites submissions that address pressing challenges in the field, from identifying novel biomarkers to developing personalized treatment strategies. With its global reach and multidisciplinary approach, ARD remains at the forefront of rheumatology research and practice.